How does epilepsy impact the pharmacotherapeutic management of patients with dementia with Lewy bodies?
Abstract
How does epilepsy impact the pharmacotherapeutic management of patients with dementia with Lewy bodies? Benjamin Cretin & Frederic Blanc To cite this article: Benjamin Cretin & Frederic Blanc (2020): How does epilepsy impact the pharmacotherapeutic management of patients with dementia with Lewy bodies?, Expert Opinion on Pharmacotherapy, DOI: 10.1080/14656566.2019.1707185 To link to this article: https://doi.org/10.1080/14656566.2019.1707185
Read the paper
Related studies
- In silico strategies for modeling RNA aptamers and predicting binding sites of their molecular targets
- Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery
- Anti-phytopathogenic and plant growth promoting potential of endophytic fungi isolated from Dysoxylum gotadhora
- Mercury toxicity causes iron and sulfur deficiencies along with oxidative injuries in alfalfa (Medicago sativa)
- Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis in vitro and in vivo
- Assessing the Protective Effect of Moringa oleifera Extract against Bone Metastasis: An In Vitro Simulated Digestion Approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.